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235 Oxygen saturation of peripheral blood and the functional capacity
of respiratory system in children with cystic ﬁbrosis
A. Cotoman1, S. Sciuca1, O. Turcu1. 1State Medical and Pharmaceutical
University, Pediatrics, Chisinau, Moldova
Aim: This study was performed to evaluate the oxygen saturation of peripheral
blood and the functional capacity of respiratory system after the physic effort in
children with cystic ﬁbrosis (CF).
Material and Methods: The study lot included 30 children (13 girls and 17 boys,
mean age 11.3±6.4 years) with CF. The control group included 28 healthy
schoolchildren. Oxygen saturation of peripheral blood (SpO2) was assessed on
pulsoximeter “Baxter”. The effort test (10 genuﬂexion) was performing to evaluate
the functional capacity of respiratory system after the physic effort in children with
cystic ﬁbrosis. SpO2 was measured before and immediately after effort test.
Results: The initial value of SpO2 96.8±0.6% in children from study group
was signiﬁcantly (p< 0.05) reduced comparative to 98±0.2% in healthy children.
SpO2 importantly decreased after the physical effort test from 96.8±0.6% to
93.1±0.9% (p< 0.05) in CF children. SpO2 values presented insigniﬁcant decline
from 98±0.2% to 96.7±1.1% in control group.
Conclusion: The effort test revealed an insufﬁcient compensatory mechanism of
respiratory function in children with cystic ﬁbrosis and is informative to evaluate
the functional capacity of respiratory system after the physic effort in these patients.
236* A multi-cycle open label study of nebulized liposomal amikacin
(Arikace™) in the treatment of cystic ﬁbrosis patients with
chronic Pseudomonas aeruginosa lung infection
P. Minic1, S. Fustic2, E. Solyom2, H. Mazurek2, Y. Antipkin2, A. Feketova2,
A. Senatorova2, E. Csiszer2, V. Kostromina2, B. Takac2, R. Ujhelyi2, R. Gupta3.
1Institute for Health Protection of Mother and Child, Belgrade, Serbia; 2CF
Arikace™ Study Group, Monmouth Junction, NJ, United States; 3Transave, Inc.,
Monmouth Junction, NJ, United States
Objective: Arikace™ is an aqueous liposomal dispersion of amikacin for inhalation
being developed for the treatment of P. aeruginosa (Pa) infection in CF pa-
tients (pts). The primary objective of the study was to evaluate the long-term effects
of multiple cycles (cy) of treatment with Arikace™.
Methods: This is a multi-cycle, open-label study conducted in 11 centers in
Europe. Pts 6 years (yr) and above who were previously enrolled in the placebo
controlled study of Arikace were consented to participate in this 6 cy, 18 month
(mo) study. Each cy is comprised of 28 days (d) of treatment with 560mg of Arikace
by inhalation with PARI eFlow® nebulizer followed by 2mo off drug. Safety,
pharmacokinetics, Pa sputum density, Quality of Life (CFQ-R) and exacerbation
rate are evaluated every 2 weeks.
Results: 48 pts were enrolled. 47 pts have completed 2 cy. 46 pts, 30 pts and
11 pts have completed 3, 4, and 5 cy respectively. Baseline Mean age is 17.3 yr;
FEV1(% pred) is 60.1%; male 41.7%; female 58.3%. Overall, Arikace™560mg
administered once daily for 5 cy is well tolerated and demonstrates adverse effects
consistent with those expected in a population of CF pts. Available data from 3 cy
show an increase above baseline in FEV1(%) of 8.5%-12.0% during the treatment
period and sustained increase of 5−10% at the end of the 2mo off drug for each
cy. Up to 1.3 log reduction in Pa was also seen. Data from additional cy will be
available at ECFS.
Conclusion: Arikace™ 560mg given once daily for 28 d for multiple cy is well
tolerated in CF pts. An increase in FEV1(%) signiﬁcantly above baseline is observed
during treatment period of each cy which is sustained during the 2mo off study
drug indicating patient beneﬁt.
237 Sidestream Plus (SS+) and PARI LC PLUS (LC+) nebulizers have
comparable delivery characteristics for CF drugs
K.C. Kesser1, D.E. Geller1. 1Nemours Children’s Clinic, Orlando, FL, United
States
Purpose: Inhaled CF drugs like rhDNase and tobramycin inhalation solution (TIS,
TOBI®) are used with speciﬁc approved nebulizers, like the LC+. If alternate nebu-
lizers are substituted, they require testing to conﬁrm similar delivery characteristics.
We tested the in vitro aerosol characteristics of the SS+ vs. the approved LC+ for
these CF drugs.
Methods: We studied 5 new nebulizers of each brand loaded with either rhD-
Nase (2.5mg) or TIS (300mg). Particle size distribution (VMD and GSD) was
determined by laser diffraction. Nebulizers were connected to a COMPAS breath
simulator; respiratory parameters (RR= 20, Vt = 500mL, I:E 1:1.5). Inspired drug
was captured on absolute ﬁlters and measured with spectrophotometry. Neb dura-
tion, residual dose (RD), inspired dose (ID), ﬁne particle dose (FPD, <5mm) and
very ﬁne particle dose (VFPD, <3mm) were determined.





LC+ (TIS) SS+ (TIS)
VMD 3.54±0.3 3.82±0.1 3.63±0.6 3.85±0.3
GSD 2.3±0.1 2.3±0.2 2.3±0.1 2.3±0.1
Duration (minutes) 5.7±0.2 5.6±0.2 13.6±1.2 13.0±1.5
Residual dose (mg) 1.6±0.2 1.8±0.2 132.8±9.3 141.1±4.5
Inspired dose (mg) 0.7±0.04 0.6±0.03 102.8±5.9 101.2±9.8
FPD (mg) 0.46±0.02 0.36±0.02 64.5±3.3 60.9±5.3
VFPD (mg) 0.32±0.02 0.25±0.01 44.9±2.3 41.5±3.6
Output (FPD/min) 0.08±0.0 0.07±0.0 4.8±0.6 4.7±0.5
Discussion: For TIS, all aerosol characteristics were very similar (<10% difference).
For rhDNase, the SS+ had a marginally larger VMD and RD, leading to a 22%
difference for FPD and VFPD (clinically irrelevant for rhDNase).
Conclusion: Based on these in vitro data, the SS+ is a viable option for aerosol
delivery of rhDNase and TIS in CF patients.
238 Is telemedicine useful in home management of cystic ﬁbrosis
patients?
S. Bella1, F. Murgia1, F. Alghisi1, V. Lucidi1. 1Bambino Gesu` Pediatric Hospital −
IRCCS, Pediatric Medicine Department, Rome, Italy
Background: In Cystic Fibrosis (CF), the more important long-term goal is to
reduce the rate of recurrent pulmonary infections. To investigate if Telehomecare
(THC) may be helpful in CF follow-up, we studied the effects of THC in a group of
patients, through FEV1 and overnight SaO2 survey, with the aim to early recognize
the relapses of pulmonary infections.
Materials and Methods: Data were collected during 4-years period. The study
involved 17 patients treated with THC, in addition to the usual protocol, for an
average period of 29.6±13.5 months. The mean age at enrolment was 15.74±5.8.
Results and Economic analysis: We recognized 136 pulmonary relapse episodes:
99 were treated at home by oral or i.v. antibiotic therapy (€ 379,833) and 37 by
hospitalization (€ 150,405), with a total cost induced of € 530,238.
Considering that, in absence of THC, all episodes would involve hospitalization,
we compared the total cost of THC patients with the cost of 136 in-patients
acutely hospitalized in the same period for chronic pathologies with similar DRG
(€ 552,840). On the other hand, in THC treated patients, the 99 avoided hospi-
talizations needed the structure to perform as many admissions, with an income
of € 422,916 that we considered a saving (€ 530,238 − € 422.916 = € 107,321.88).
The balance (€ 552.840 − € 107.321) shows a saving of € 445,519 (€ 89,103/year,
considering a 5 years period).
Conclusions: We conclude that our experience was undoubtedly positive, because
in THC treated CF patients, we obtained a more stable pulmonary function in front
of a null cost. The datum must be however conﬁrmed overtime by further studies.
